Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1)

Transient receptor potential vanilloid 1 (TRPV1) has emerged as a promising therapeutic target. While radiolabeled resiniferatoxin (RTX) has provided a powerful tool for characterization of vanilloid binding to TRPV1, TRPV1 shows 20-fold weaker binding to the human TRPV1 than to the rodent TRPV1. We now describe a tritium radiolabeled synthetic vanilloid antagonist, 1-((2-(4-(methyl-[³H])­piperidin-1-yl-4-[³H])-6-(trifluoromethyl)­pyridin-3-yl)­methyl)-3-(3-oxo-3,4-dihydro-2<i>H</i>-benzo­[<i>b</i>]­[1,4]­oxazin-8-yl)­urea ([³H]­MPOU), that embodies improved absolute affinity for human TRPV1 and improved synthetic accessibility